Femasys Stock News

Zacks Investment Research upgraded shares of Femasys (NASDAQ:FEMY) from a hold rating to a buy rating in a research note released on Friday morning, Zacks.com reports. They currently have $4.50 target price on the stock. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as []

Femasys'' lock-up period will end on Wednesday, December 15th. Femasys had issued 2,650,000 shares in its public offering on June 18th. The total size of the offering was

Femasys (NASDAQ:FEMY) lock-up period will end on Wednesday, December 15th. Femasys had issued 2,650,000 shares in its public offering on June 18th. The total size of the offering was $34,450,000 based on an initial share price of $13.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following [] The post Femasys Inc.s Lock-Up Period Will End on December 15th (NASDAQ:FEMY) appeared first on ETF Daily News .

Femasys (NASDAQ:FEMY) lock-up period will end on Wednesday, December 15th. Femasys had issued 2,650,000 shares in its IPO on June 18th. The total size of the offering was $34,450,000 based on an initial share price of $13.00. After the end of Femasys lock-up period, restrictions preventing major shareholders and company insiders from selling shares in []

Femasys (NASDAQ:FEMY) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage presently has a $5.00 price target on the stock. Zacks Investment Researchs price target suggests a potential upside of 7.30% from the companys current []

Zacks Investment Research upgraded shares of Femasys (NASDAQ:FEMY) from a hold rating to a buy rating in a research note released on Tuesday, Zacks.com reports. The brokerage currently has $5.00 price objective on the stock. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as [] The post Femasys (NASDAQ:FEMY) Lifted to Buy at Zacks Investment Research appeared first on ETF Daily News .

SeaSpine (NASDAQ:SPNE) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Profitability This table compares SeaSpine and Femasys net margins, return on equity and return on assets. Net [] The post Financial Analysis: SeaSpine (NASDAQ:SPNE) vs. Femasys (NASDAQ:FEMY) appeared first on ETF Daily News .

Clear Creek Financial Management LLC acquired a new position in shares of Femasys Inc. (NASDAQ:FEMY) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 23,524 shares of the companys stock, valued at approximately $162,000. Clear Creek Financial Management LLC owned about 0.20% of Femasys as of its []

Femasys (NASDAQ:FEMY) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Thursday, Zacks.com reports. The firm currently has a $4.50 target price on the stock. Zacks Investment Researchs price objective would indicate a potential downside of 0.88% from the companys current price. According [] The post Femasys (NASDAQ:FEMY) Lifted to Buy at Zacks Investment Research appeared first on ETF Daily News .

Zacks Investment Research upgraded shares of Femasys (NASDAQ:FEMY) from a hold rating to a buy rating in a research report released on Thursday morning, Zacks.com reports. They currently have $7.25 target price on the stock. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as []

Femasys (NASDAQ:FEMY) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The companys []

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthc

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEM